Form 4: Kyverna Therapeutics CEO Warner Weston Biddle Acquires Stock Options
SEC Form 4 Filing
Kyverna Therapeutics CEO Warner Weston Biddle reports acquisition of stock options on September 16, 2024.
Summary
- On September 16, 2024, Warner Weston Biddle, CEO of Kyverna Therapeutics, acquired 2,579,259 stock options with an exercise price of $6.89.
- These options vest over time, with 1/4th vesting on September 16, 2025, and the remaining 1/48th vesting monthly thereafter, contingent upon continuous service.
- Following the transaction, Biddle directly owns 2,579,259 derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and suggests confidence in the company's future, but it's not overwhelmingly positive.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The vesting schedule indicates a long-term incentive plan for the CEO, aligning his interests with the company's long-term success.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management incentives with shareholder value.
Comparison to Industry Standards
- Executive compensation packages, including stock options, are standard practice in the biotech industry to attract and retain talent.
- Companies like Gilead Sciences and Amgen also utilize stock options as part of their executive compensation plans.
- The vesting schedule is typical, designed to incentivize long-term commitment and performance.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CEO to drive long-term value.
- Employees may see this as a sign of stability and potential growth for the company.
Key Dates
| Date | Description |
|---|---|
| 09/16/2024 | Date of the stock option grant and transaction. |
| 09/16/2025 | Date when 1/4th of the stock options begin to vest. |
| 09/16/2034 | Expiration date of the stock options. |
| 09/18/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.